MX2015012991A - Anticuerpos anti-cd52. - Google Patents

Anticuerpos anti-cd52.

Info

Publication number
MX2015012991A
MX2015012991A MX2015012991A MX2015012991A MX2015012991A MX 2015012991 A MX2015012991 A MX 2015012991A MX 2015012991 A MX2015012991 A MX 2015012991A MX 2015012991 A MX2015012991 A MX 2015012991A MX 2015012991 A MX2015012991 A MX 2015012991A
Authority
MX
Mexico
Prior art keywords
antibodies
fragments
antigen
cancer
treat
Prior art date
Application number
MX2015012991A
Other languages
English (en)
Inventor
Huawei Qiu
Ronnie Rong Wei
Clark Qun Pan
Rebecca Sendak
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50391542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015012991(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2015012991A publication Critical patent/MX2015012991A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan anticuerpos anti-CD52 humana y fragmentos de unión a antígeno de los mismos. También se proporcionan ácidos nucleicos aislados, vectores recombinantes y células huésped para preparar los anticuerpos y fragmentos. Los anticuerpos y fragmentos se pueden usar en aplicaciones terapéuticas para tratar, por ejemplo, enfermedades autoinmunes, cáncer y rechazo de injertos.
MX2015012991A 2013-03-15 2014-03-13 Anticuerpos anti-cd52. MX2015012991A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361794576P 2013-03-15 2013-03-15
PCT/US2014/026159 WO2014151644A2 (en) 2013-03-15 2014-03-13 Anti-cd52 antibodies

Publications (1)

Publication Number Publication Date
MX2015012991A true MX2015012991A (es) 2015-12-15

Family

ID=50391542

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012991A MX2015012991A (es) 2013-03-15 2014-03-13 Anticuerpos anti-cd52.

Country Status (36)

Country Link
US (2) US9708407B2 (es)
EP (1) EP2970467B1 (es)
JP (2) JP6482524B2 (es)
KR (1) KR20150131286A (es)
CN (1) CN105209495B (es)
AR (1) AR095199A1 (es)
AU (1) AU2014233685B2 (es)
BR (1) BR112015022464A2 (es)
CA (1) CA2906539A1 (es)
CL (1) CL2015002705A1 (es)
CR (1) CR20150547A (es)
CY (1) CY1121795T1 (es)
DK (1) DK2970467T3 (es)
DO (1) DOP2015000211A (es)
EA (1) EA031730B1 (es)
ES (1) ES2710976T3 (es)
GT (1) GT201500267A (es)
HK (1) HK1219963A1 (es)
HR (1) HRP20190085T1 (es)
HU (1) HUE041796T2 (es)
IL (1) IL241410A0 (es)
LT (1) LT2970467T (es)
MA (1) MA38485A1 (es)
MX (1) MX2015012991A (es)
NZ (1) NZ631473A (es)
PE (1) PE20151757A1 (es)
PH (1) PH12015501932A1 (es)
PL (1) PL2970467T4 (es)
PT (1) PT2970467T (es)
SG (1) SG11201506932SA (es)
SI (1) SI2970467T1 (es)
TN (1) TN2015000415A1 (es)
TR (1) TR201900638T4 (es)
TW (1) TWI644923B (es)
UY (1) UY35440A (es)
WO (1) WO2014151644A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010249003B2 (en) 2009-05-13 2015-08-20 Genzyme Corporation Anti-human CD52 immunoglobulins
CN102438654A (zh) 2009-05-13 2012-05-02 基酶有限公司 治疗狼疮的方法和组合物
EP3691169B1 (en) * 2014-01-28 2022-03-09 Huawei Technologies Co., Ltd. Data transmission indication method, access point and terminal
US20200299399A1 (en) * 2017-04-21 2020-09-24 Genzyme Corporation Treatment of Multiple Sclerosis with Anti-CD52 Antibodies
CN111727056A (zh) * 2018-02-13 2020-09-29 默沙东公司 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法
WO2021022044A1 (en) * 2019-07-31 2021-02-04 Forty Seven, Inc. Depletion regimes for engineered t-cell or nk-cell therapy
WO2024038839A1 (ja) * 2022-08-15 2024-02-22 国立大学法人 東京大学 糸状菌を用いた免疫グロブリンまたは多量体免疫グロブリンの製造方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0271581B1 (en) 1986-04-17 1993-01-13 Kyowa Hakko Kogyo Co., Ltd. Novel compounds dc-88a and dc-89a1 and process for their preparation
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
JP2598116B2 (ja) 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
JP2510335B2 (ja) 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9108056D0 (en) 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5269388A (en) 1991-11-12 1993-12-14 Stress-Tek, Inc. Weighing bed
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
DE69533277T2 (de) 1994-04-22 2005-07-21 Kyowa Hakko Kogyo Co., Ltd. Dc-89 derivat
US5550246A (en) 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
CN1202128C (zh) 1998-12-08 2005-05-18 拜奥威神有限公司 修饰蛋白的免疫原性
NZ517772A (en) 1999-11-24 2004-03-26 Immunogen Inc Cytotoxic agents comprising taxanes and their therapeutic use
CA2401342C (en) 2000-03-03 2010-08-03 Cambridge Antibody Technology Limited Human antibodies against eotaxin and their use
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20020132983A1 (en) 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
AU2002362197A1 (en) 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
WO2004042032A2 (en) 2002-11-01 2004-05-21 The Ohio State University Research Foundation Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
CN1225480C (zh) 2002-12-18 2005-11-02 马菁 抗cd52单克隆抗体、其编码序列及应用
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
CA2520830A1 (en) 2003-03-31 2004-10-14 Kirin Beer Kabushiki Kaisha Method for inducing differentiation and/or proliferating regulatory t cells using anti-cd52 antibodies and pharmaceutical composition therefor
CA2526120A1 (en) 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
CA2544365A1 (en) 2003-11-01 2005-05-12 Biovation, Ltd. Modified anti-cd52 antibody
US20060204496A1 (en) 2003-11-28 2006-09-14 Tetsuo Kojima Agonist antibody against heteroreceptor
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
CN101238150A (zh) 2005-05-24 2008-08-06 阿维斯塔金格兰技术有限公司 用于治疗慢性淋巴细胞性白血病的抗cd52单克隆抗体的重组生产方法
NZ564092A (en) * 2005-05-27 2010-05-28 Biogen Idec Inc TWEAK binding antibodies
BRPI0620797A2 (pt) 2005-12-30 2011-11-22 Merck Patent Ges Mit Beschonkter Haftung anticorpos anti-il-6 que previnem a ligação de il-6 complexado com il-6ralfa a gp130
PL2380585T3 (pl) 2006-04-12 2015-11-30 Genzyme Corp Sposoby leczenia chorób autoimmunologicznych
US9498528B2 (en) 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
KR101583587B1 (ko) 2006-09-13 2016-01-08 젠자임 코포레이션 캠패스-1ｈ에 의한 다발성 경화증 (ｍｓ)의 치료
CN103933573A (zh) * 2007-02-28 2014-07-23 默沙东公司 用于治疗免疫病症的联合治疗
WO2009000406A1 (en) 2007-06-22 2008-12-31 Bayer Healthcare Ag Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease
EP2429584A4 (en) 2009-05-13 2013-02-20 Genzyme Corp TREATMENT PROCEDURE AND COMPOSITIONS
AU2010249003B2 (en) * 2009-05-13 2015-08-20 Genzyme Corporation Anti-human CD52 immunoglobulins
CN102438654A (zh) 2009-05-13 2012-05-02 基酶有限公司 治疗狼疮的方法和组合物
NZ598063A (en) * 2009-07-15 2014-07-25 Genentech Inc Aimm Therapeutics B V Gram-positive bacteria specific binding compounds
EP2593594B1 (en) * 2010-07-16 2017-09-27 Adimab, LLC Antibody libraries

Also Published As

Publication number Publication date
IL241410A0 (en) 2015-11-30
WO2014151644A3 (en) 2015-01-15
PL2970467T3 (pl) 2019-07-31
US9708407B2 (en) 2017-07-18
JP6482524B2 (ja) 2019-03-13
BR112015022464A2 (pt) 2017-10-24
MA38485A1 (fr) 2017-06-30
CN105209495B (zh) 2020-06-26
JP2019069960A (ja) 2019-05-09
US20170349665A1 (en) 2017-12-07
CN105209495A (zh) 2015-12-30
DK2970467T3 (en) 2019-02-11
KR20150131286A (ko) 2015-11-24
JP2016518333A (ja) 2016-06-23
LT2970467T (lt) 2019-02-11
WO2014151644A2 (en) 2014-09-25
EP2970467B1 (en) 2018-10-17
TWI644923B (zh) 2018-12-21
CR20150547A (es) 2016-01-08
ES2710976T3 (es) 2019-04-29
TR201900638T4 (tr) 2019-03-21
AR095199A1 (es) 2015-09-30
EP2970467A2 (en) 2016-01-20
AU2014233685A1 (en) 2015-10-01
UY35440A (es) 2014-10-31
CA2906539A1 (en) 2014-09-25
HK1219963A1 (zh) 2017-04-21
HRP20190085T1 (hr) 2019-03-08
AU2014233685B2 (en) 2019-02-28
TN2015000415A1 (en) 2017-01-03
PE20151757A1 (es) 2015-12-03
PT2970467T (pt) 2019-01-28
EA031730B1 (ru) 2019-02-28
CL2015002705A1 (es) 2016-04-22
NZ631473A (en) 2017-09-29
PH12015501932A1 (en) 2016-01-04
TW201522373A (zh) 2015-06-16
SG11201506932SA (en) 2015-09-29
DOP2015000211A (es) 2015-11-30
EA201591796A1 (ru) 2016-01-29
CY1121795T1 (el) 2020-07-31
HUE041796T2 (hu) 2019-05-28
US20160024219A1 (en) 2016-01-28
GT201500267A (es) 2017-12-15
SI2970467T1 (sl) 2019-03-29
PL2970467T4 (pl) 2019-07-31

Similar Documents

Publication Publication Date Title
TN2015000415A1 (en) Anti-cd52 antibodies
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MX2023000818A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
MX2023001834A (es) Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
AU2016243120B2 (en) Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer
MX2018004503A (es) Receptores de antigeno quimerico anti-cd30.
PH12016500275A1 (en) Antibodies
MX2019002903A (es) Receptores de antigeno quimerico que comprenden dominios de tipo iii de fibronectina especificos del bcma y usos de estos.
MX2016012479A (es) Miembros de unión al factor de necrosis tumoral (tnf) alfa.
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
AU2016335217A8 (en) Antigen receptors and uses thereof
EA201791918A1 (ru) Модификация белков клеток-хозяев
MX2015012281A (es) Proteinas de union a tnf mejoradas.
MX2018003445A (es) Expresion de proteinas que contienen fc.
EP3494231A4 (en) METHODS FOR IDENTIFYING NEW PROTEINS AND NEW ANTIGENS IN CANCER CELLS
JO3545B1 (ar) تركيبات الناقل-الجسم المضاد وطرق صناعتها واستخدامها
EA201792665A1 (ru) Антитела против ctla-4 и способы их применения